Table 3 Univariate and multivariate analysis of prognostic factors for progression-free survival and overall survival (n = 48)
Variable | No. of patients | Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|---|---|
2-y Survival rate (%) | PFS | OS | |||||||
PFS | p-value | OS | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | ||
Age | |||||||||
≥ 50 years | 29 | 35.6 | 36.8 | 0.52 (0.27–1.01) | 0.053 | ||||
< 50 years | 19 | 10.5 | 0.034 | 26.3 | 0.096 | Reference | |||
Size of the cervical tumor | |||||||||
≥ 4-cm | 39 | 21.7 | 28.2 | ||||||
< 4-cm | 9 | 38.1 | 0.338 | 51.9 | 0.207 | ||||
Histological subtype | |||||||||
Squamous cell carcinoma | 39 | 28.0 | 38.5 | ||||||
Non-squamous cell carcinoma | 9 | 11.1 | 0.064 | 0 | 0.002 | ||||
ECOG performance status score | |||||||||
0 | 33 | 27.6 | 35.2 | ||||||
1–2 | 15 | 16.7 | 0.466 | 26.7 | 0.654 | ||||
Pre-treatment Hb (g/dL) | |||||||||
> 10 | 37 | 23.1 | 29.7 | ||||||
≤ 10 | 11 | 27.7 | 0.622 | 41.6 | 0.385 | ||||
Pre-treatment WBC(10^9 /L) | |||||||||
> 10 | 8 | 25.0 | 25.0 | ||||||
≤ 10 | 40 | 23.8 | 0.415 | 34.0 | 0.330 | ||||
Oligometastasis | |||||||||
Yes | 21 | 37.5 | 52.4 | ||||||
No | 27 | 12.2 | 0.037 | 16.3 | 0.042 | ||||
Bone metastasis | |||||||||
Yes | 28 | 23.1 | 33.9 | ||||||
No | 20 | 25.5 | 0.716 | 30 | 0.662 | ||||
Number of organ metastasis | |||||||||
Single | 37 | 26.7 | 37.8 | ||||||
Multiple | 11 | 18.2 | 0.371 | 12.1 | 0.160 | ||||
Lung metastasis | |||||||||
Yes | 14 | 8.2 | 14.3 | ||||||
No | 34 | 30.3 | 0.116 | 40 | 0.115 | ||||
Liver metastasis | |||||||||
Yes | 10 | 24.3 | 25 | ||||||
No | 38 | 26.7 | 0.805 | 34.2 | 0.656 | ||||
Distant lymph node metastasis | |||||||||
Yes | 20 | 16 | 16.9 | ||||||
No | 28 | 29.5 | 0.203 | 42.9 | 0.063 | ||||
Treatment mode | |||||||||
Group A | 36 | 30.4 | 38.9 | 0.40 (0.19–0.84) | 0.015 | 0.32 (0.15–0.67) | 0.003 | ||
Group B | 12 | 0 | 0.008 | 12.5 | 0.002 | Reference | Reference | ||